- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Lenvatinib May Provide Survival Benefit With Manageable Toxicities in Recurrent HCC After Liver Transplantation
January 21, 2022
In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.
Efficacy Sustained at 2 Years With Nivolumab Plus Chemo in Gastric/GEJ Cancer
January 21, 2022
In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.
Part 2: Anderson Reviews Niraparib’s Efficacy in High-Risk Ovarian Cancer
January 21, 2022
During a live virtual event, Matthew L. Anderson, MD, PhD, discussed the results of the PRIMA study of niraparib in patients with wild-type and BRCA-mutated ovarian cancer.
TACE Plus Lenvatinib and a PD-1 Antibody Appears Safe, Effective in Advanced uHCC
January 21, 2022
The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.
Sintilimab Improves Response, But Not Survival in Pancreatic Cancer
January 21, 2022
Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.
Pembrolizumab Plus BSC Shows Significant Survival Benefit in Advanced HCC
January 21, 2022
In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.
Treating Gastric Cancer in the Near Future
January 21, 2022
During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.
Oral Fluoropyrimidine Prolongs Survival as Adjuvant Treatment for Biliary Tract Cancer
January 21, 2022
In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.
Single-Agent Adagrasib Achieves High Disease Control Rate in Pretreated PDAC and Other GI Cancers
January 21, 2022
According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.
FDA Grants Orphan Drug Designation to MT-601 for Pancreatic Cancer Treatment
January 21, 2022
With an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial.
Frontline Pembrolizumab Noninferior But Not Superior to Frontline Chemo in PD-L1+ Gastric/GEJ Adenocarcinoma
January 21, 2022
Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Phase 3 Trial to Determine the Potential Superiority of Pembrolizumab/Lenvatinib vs Chemotherapy in Advanced Endometrial Cancer
January 21, 2022
Pending results from the ENGOT-en9/LEAP-001 will determine whether the combination of pembrolizumab and lenvatinib prolongs survival more than chemotherapy in patients with endometrial cancer.